Skip to main content

BENEFICIOS TERAPEUTICOS DE LOS CANNABINOIDES COMO AGENTES DE DIFERENCIACION EN CANCER DE MAMA

PID2022-136508OA-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2022
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSIDAD COMPLUTENSE DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Docta Complutense
Publication Artículo científico (JournalArticle)

Tumor ecology and the paradox of clean margins in multicentric breast cancer: an exploratory organoid-based functional study

  • García Martínez-Illescas, Nuria
  • Martín Zapater, Estrella
  • Quezada Gutiérrez, Camila Ignacia
  • Yébenes, Laura
  • Payo Payo, Ana
  • Frías Aldeguer, Laura
  • Salazar Roa, María
The gene-centric view of cancer has provided important mechanistic insights, but does not fully account for the clinical heterogeneity observed in complex cases. An eco-evolutionary framework instead conceptualizes tumors as dynamic systems shaped by interactions among malignant clones, stromal components, immune populations and the surrounding microenvironment. Multicentric/multifocal breast cancer (MMBC) provides a relevant context in which to explore this biological complexity. Using patient-derived organoids, we observed that organoids derived from histologically tumor-free margins can display stem-like and basal-like features under defined culture conditions, whereas those from primary tumor regions may exhibit more differentiated phenotypes. These observations suggest that histological margin status alone may not fully capture the functional heterogeneity of peritumoral tissue. Our findings support the hypothesis that biological influences within the margin region may contribute to shaping cellular phenotypes beyond the presence of overt malignant cells. Overall, this study highlights the potential value of integrating organoid-based functional approaches with eco-evolutionary concepts to further investigate the biological landscape of the peritumoral field in MMBC.
Docta Complutense
Publication Artículo científico (JournalArticle)

Cannabinoid CB2 receptor drives trastuzumab resistance and predicts durable anti-HER2 response

  • Seijo Vila, Marta
  • Balsinde, Sofía A.
  • Blasco Benito, Sandra
  • Tundidor, Isabel
  • Rubert Hernández, María
  • Montero Calle, Ana
  • Barderas Manchado, Rodrigo
  • Kilpatrick, Laura E.
  • Platt, Simon
  • Karsai, Noemi
  • Philps, Isabel
  • Antón Hurtado, Olga María
  • Gómez Domínguez, Déborah
  • Pérez de Castro, Ignacio
  • González Lois, Carmen
  • García Fresnadillo, Diego
  • Silvestre Egea, Gala
  • Sánchez López, Antonio J.
  • Ramírez Medina, Esther
  • Rivas Prieto, María Catalina
  • Almoguera Pérez Cejuela, Belén
  • Manso, Luis
  • Zazo, Sandra
  • López Ejeda, Noemí
  • Palomino Duque, Francisco
  • Turienzo Durán, María
  • García Martínez-Illescas, Nuria
  • Salazar Roa, María
  • Castillo Lluva, Sonia
  • Hill, Stephen J.
  • Guzmán Pastor, Manuel
  • Pérez Gómez, Eduardo
  • Sánchez García, María Cristina
Acquired or innate lack of response to standard HER2-targeted therapies remains a clinical issue in patients with HER2-positive breast cancer. Here, we investigated the role of the cannabinoid CB2 receptor (CB2R) in trastuzumab resistance. In human breast cancer samples, a decreased expression of HER2-CB2R heterodimers following neoadjuvant treatment, due to CB2R downregulation, was linked to poor long-term outcomes. Using various preclinical models, we demonstrate that CB2R drives trastuzumab resistance. Mechanistically, CB2R loss enabled cancer cells to evade antitumor IFN-γ signaling while promoting a shift from HER2-CB2R to HER2-EGFR heterodimers, thus reducing dependence on HER2 and increasing reliance on EGFR-mediated pathways. Moreover, EGFR inhibition restored trastuzumab sensitivity. In summary, we reveal an unprecedented role for CB2R as a key regulator of oncogenic and immune signaling in response to anti-HER2 therapy and its potential as a predictive biomarker of therapeutic efficacy. We also propose dual HER2/EGFR targeting and non-CB2R-selective cannabinoid therapies as potential strategies to overcome CB2R-mediated trastuzumab resistance. Together, these findings position the endocannabinoid system as a pivotal and actionable node to elucidate, anticipate, and counteract resistance to HER2-targeted therapies.